INFI insider filings
INFINITY PHARMACEUTICALS, INC. — 29 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2023-09-12. Screen INFI transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for INFI between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.
Recent insider filings — INFINITY PHARMACEUTICALS, INC.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2023-09-12 | 4 | Perkins Adelene Q — Director | Option exercise (M): 768,133 · Sale (S): 410,196 @ $0.07 · Option exercise (M): 768,133 (derivative) @ $0 | EDGAR |
| 2022-08-04 | 4 | Peluso Stephane — Chief Scientific Officer | Option exercise (M): 50,000 · Sale (S): 14,994 @ $0.66 · Option exercise (M): 50,000 (derivative) @ $0 | EDGAR |
| 2022-06-16 | 4 | EVNIN ANTHONY B — Director | Grant/award (A): 46,378 @ $0.68 · Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
| 2022-06-16 | 4 | BEIER DAVID W — Director | Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
| 2022-06-16 | 4 | GAYNOR RICHARD — Director | Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
| 2022-06-16 | 4 | Agresta Samuel — Director | Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
| 2022-06-16 | 4 | SELBY NORMAN C — Director | Grant/award (A): 45,000 (derivative) @ $0 · Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2022-06-16 | 4 | SCHWARTZ BRIAN — Director | Grant/award (A): 30,919 @ $0.68 · Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
| 2022-03-31 | 4 | KANGO SUJAY — Director | Grant/award (A): 90,000 (derivative) @ $0 | EDGAR |
| 2022-01-12 | 4 | Perkins Adelene Q — Chief Executive Officer, Director | Grant/award (A): 576,100 (derivative) @ $0 | EDGAR |
| 2022-01-12 | 4 | BLOCH LAWRENCE E — President | Grant/award (A): 335,000 (derivative) @ $0 | EDGAR |
| 2022-01-12 | 4 | Tasker Seth A — Chief Business Officer | Grant/award (A): 225,000 (derivative) @ $0 | EDGAR |
| 2022-01-12 | 4 | Peluso Stephane — Chief Scientific Officer | Grant/award (A): 87,027 (derivative) @ $0 | EDGAR |
| 2022-01-12 | 4 | Ilaria Robert Jr. — Chief Medical Officer | Grant/award (A): 87,472 (derivative) @ $0 | EDGAR |
| 2021-09-10 | 4 | SCHWARTZ BRIAN — Director | Grant/award (A): 60,000 (derivative) @ $0 | EDGAR |
| 2021-09-03 | 4 | Ilaria Robert Jr. — Chief Medical Officer | Grant/award (A): 300,000 (derivative) @ $0 | EDGAR |
| 2021-08-03 | 4 | Peluso Stephane — Chief Scientific Officer | Grant/award (A): 250,000 (derivative) @ $0 · Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2021-06-11 | 4 | BEIER DAVID W — Director | Grant/award (A): 3,061 @ $3.43 · Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2021-06-11 | 4 | Agresta Samuel — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2021-06-11 | 4 | SELBY NORMAN C — Director | Grant/award (A): 30,000 (derivative) @ $0 · Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2021-06-11 | 4 | GAYNOR RICHARD — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2021-06-11 | 4 | EVNIN ANTHONY B — Director | Grant/award (A): 3,061 @ $3.43 · Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2021-05-18 | 4 | SELBY NORMAN C — Director | Option exercise (M): 5,000 @ $0.92 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
| 2021-02-19 | 4 | BVF PARTNERS L P/IL BIOTECHNOLOGY VALUE FUND L P BVF I GP LLC BIOTECHNOLOGY VALUE FUND II LP BVF II GP LLC Biotechnology Value Trading Fund OS LP BVF Partners OS Ltd. BVF GP HOLDINGS LLC BVF INC/IL LAMPERT MARK N | Holdings only — no transactions reported | EDGAR |
| 2021-02-16 | 4 | BVF PARTNERS L P/IL — 10% owner BIOTECHNOLOGY VALUE FUND L P BVF I GP LLC BIOTECHNOLOGY VALUE FUND II LP BVF II GP LLC Biotechnology Value Trading Fund OS LP BVF Partners OS Ltd. BVF GP HOLDINGS LLC — 10% owner BVF INC/IL — 10% owner LAMPERT MARK N — 10% owner | Sale (S): 1,215,491 @ $5.37 · Sale (S): 892,467 @ $5.37 · Sale (S): 152,127 @ $5.37 | EDGAR |
| 2021-01-26 | 4 | BVF PARTNERS L P/IL — 10% owner BIOTECHNOLOGY VALUE FUND L P BVF I GP LLC BIOTECHNOLOGY VALUE FUND II LP BVF II GP LLC Biotechnology Value Trading Fund OS LP BVF Partners OS Ltd. BVF GP HOLDINGS LLC — 10% owner BVF INC/IL — 10% owner LAMPERT MARK N — 10% owner | Sale (S): 2,821,663 @ $4.14 · Sale (S): 2,458,838 @ $4.14 · Sale (S): 568,019 @ $4.14 | EDGAR |
| 2020-12-23 | 4 | Tasker Seth A — Chief Business Officer | Grant/award (A): 250,000 (derivative) @ $0 | EDGAR |
| 2020-12-23 | 4 | BLOCH LAWRENCE E — President | Grant/award (A): 335,000 (derivative) @ $0 | EDGAR |
| 2020-12-23 | 4 | Perkins Adelene Q — Chief Executive Officer, Director | Grant/award (A): 485,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — INFINITY PHARMACEUTICALS, INC.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2023-09-29 | 8-K | 1.03 — Bankruptcy or Receivership 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2023-09-13 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
| 2023-09-11 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
| 2023-09-01 | 8-K | ? 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8.01 — Other Events | EDGAR |
| 2023-07-25 | 8-K | ? 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-07-24 | 8-K | 1.02 — Termination of a Material Definitive Agreement 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-07-14 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2023-07-03 | 8-K | 8.01 — Other Events | EDGAR |
| 2023-06-30 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
| 2023-06-20 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=INFI returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs